Detalhe da pesquisa
1.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990608
2.
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
J Clin Oncol
; 40(8): 837-846, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928708
3.
Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries.
Trials
; 11: 104, 2010 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21073691